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Abstract
Introduction: Autoreactivity to histones is a pervasive feature of several human autoimmune disorders, including
systemic lupus erythematosus (SLE). Specific post-translational modifications (PTMs) of histones within neutrophil
extracellular traps (NETs) may potentially drive the process by which tolerance to these chromatin-associated
proteins is broken. We hypothesized that NETs and their unique histone PTMs might be capable of inducing
autoantibodies that target histones.
Methods: We developed a novel and efficient method for the in vitro production, visualization, and broad profiling
of histone-PTMs of human and murine NETs. We also immunized Balb/c mice with murine NETs and profiled their
sera on autoantigen and histone peptide microarrays for evidence of autoantibody production to their
immunogen.
Results: We confirmed specificity toward acetyl-modified histone H2B as well as to other histone PTMs in sera
from patients with SLE known to have autoreactivity against histones. We observed enrichment for distinctive
histone marks of transcriptionally silent DNA during NETosis triggered by diverse stimuli. However, NETs derived
from human and murine sources did not harbor many of the PTMs toward which autoreactivity was observed in
patients with SLE or in MRL/lpr mice. Further, while murine NETs were weak autoantigens in vivo, there was only
partial overlap in the immunoglobulin G (IgG) and IgM autoantibody profiles induced by vaccination of mice with
NETs and those seen in patients with SLE.
Conclusions: Isolated in vivo exposure to NETs is insufficient to break tolerance and may involve additional factors
that have yet to be identified.
Introduction
Neutrophil extracellular traps (NETs) were first
described in 2004 as web-like structures that trap and
neutralize microbes at sites of infection [1]. Neutrophils,
a first line of defense against microorganisms during
such encounters, produce these highly modified chroma-
tin webs through a cellular suicide program distinct
from apoptosis and necrosis, termed “NETosis” [2]. In
addition to neutrophil antimicrobial proteins, NETs are
comprised of chromatin components, including histones.
Because NETs are extracellular and typically in an
inflammatory environment, their proximity to compo-
nents of the adaptive and innate immune systems might
provide an immunogenic substrate for autoimmune
responses during regular encounters with commensal
and pathogenic microbes.
Indeed, an emerging and growing body of literature
supports a putative link between NETs and autoimmu-
nity. Baker et al. identified circulating NETs in the
blood of pediatric patients with malaria, a subset of
whom also exhibited signs of an autoimmune response
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[3]. A more recent study identified a subset of patients
with lupus nephritis whose sera were impaired in
degrading NETs, suggesting that such impairment could
be pathogenic [4]. Two recent studies reported activa-
tion of plasmacytoid dendritic cells (pDCs) by com-
plexes between NETs and antimicrobial peptides such
as LL-37 that engage Toll-like receptor 9 (TLR9) and
result in Type I interferon production, a process known
to be associated with SLE [5,6].
Anti-histone antibodies are found in 70% to 80% of
patients with idiopathic SLE [7], and in more than 90%
of patients with drug-induced lupus [7,8]. Furthermore,
the presence of such antibodies is a highly specific sero-
logical feature that distinguishes both of these lupus var-
iants from other autoimmune diseases [9,10]. Patients
with drug-induced lupus due to procainamide or hydra-
lazine most commonly do not have antibodies directed
against non-histone nuclear antigens, a serological fea-
ture frequently used to distinguish between drug-
induced and idiopathic SLE [7,11-13]. Further, the ten-
dency and degree to which such drugs are covalently
modified by acetylation (a common post-translational
modification of histones) critically influences their ten-
dency to induce anti-histone antibodies and lupus
[14,15]. Finally, the capacity of several drugs to serve as
neutrophil myeloperoxidase substrates in vitro is asso-
ciated with their ability to induce lupus in vivo [16].
Collectively, these findings suggest potential mechanisms
linking post-translational histone modifications to
induction of autoimmunity, with neutrophils contribut-
ing to this process.
Over the last decade, a significant body of emerging
evidence has supported a role for PTMs of several auto-
antigens in the pathogenesis of diverse autoimmune dis-
eases [17,18]. Modified autoantigens have been shown
to relocalize to other cellular compartments including
apoptotic blebs during cell stress [19]. Such modified
autoantigens have been proposed to elicit immune
responses because they appear foreign to T and B cells
or because the modifications may alter their processing
and presentation by antigen presenting cells (reviewed
in [20]). For example, many diverse autoantigens are
substrates for cleavage by caspases, and some autoanti-
bodies are better able to recognize cleaved antigens than
native counterparts [21]. Similarly, we and others have
shown that many different antigens are phosphorylated:
for instance, transient phosphorylation of serine/argi-
nine-rich (SR) splicing family members during apoptosis
leads to their association with the U1-snRNP and U3-
snoRNP autoantigen complexes, and can commonly be
recognized by SLE sera in a phosphorylation-dependent
manner [22-27].
However, to date, few studies have specifically exam-
ined the role of post-translational modifications (PTMs)
in the context of NETs within SLE. For instance, while
van Bavel and colleagues identified in a subset of
patients with SLE autoantibodies against acetylated his-
tone H2B tails [28], histone H4 [29] and histone
H3K27Me3 [30], the relationship of these marks to
those within NETs remains unclear, and SLE autoanti-
bodies may recognize other histone PTMs. Such PTMs
may play an important role in SLE pathogenesis, since a
unifying characteristic of most SLE-associated autoanti-
gens is that they contain either DNA or RNA with
many of the associated protein components targeted by
PTMs [17].
While NETs represent a strong candidate as a source
of diverse exposed cryptic epitopes that may lead to
autoimmunity, only a single PTM found on NET his-
tones has been well-characterized. Specifically, NET his-
tones harbor citrulline residues, a PTM mediated by the
peptidyl arginine deiminase (PAD) family of enzymes
during reversible deimination of arginine residues
[31,32]. Autoantibodies directed against citrullinated
proteins are highly specific at diagnosis of rheumatoid
arthritis (RA), and have also been found in a collagen-
induced arthritis model of RA [26,27]. Citrullination of
histones arising from PAD-4 activity during NETosis
was recently shown to be a specific marker of NETs and
necessary for NET formation [31,32]. Accordingly, anti-
bacterial innate immunity is considerably inhibited in
PAD-4-deficient mice [33]. To date, while the protein
components of NETs have been systematically identified
[34], no studies have broadly profiled the PTM state of
their histones.
We, therefore, hypothesized that NETs and unique
associated histone PTMs are capable of inducing auto-
antibodies that target histones and lead to subsequent
autoimmunity. We devised novel and efficient methods
for production, characterization and visualization of
NETs in vitro. We biochemically characterized the
PTMs accompanying in vitro NETosis and broadly pro-
filed the in vivo humoral immune responses of patients
with SLE and mice immunized with NETS by applying
multiple proteomic approaches, including autoantigen
microarrays [35], PTM-modified histone peptide arrays
[36] and a high-throughput immunoblotting assay (mod-
ified Multiple Antigen Blot Assay, MABA) [37]. Consis-
tent with recent findings [28], we found that sera from
patients with SLE reacted to acetyl-H2B histone pro-
teins. In broadly profiling the PTMs of NETs from
human and mouse sources, we observed their enrich-
ment for distinctive PTMs characteristic of transcrip-
tional silencing. However, these marks only partly
overlapped with autoantibody profiles in histone-reactive
sera of patients with SLE and with those in sera from
mice prone to spontaneous autoimmunity. Nonetheless,
we found that NETs could serve as weak autoantigens
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in vivo, capable of eliciting mouse IgG and IgM
responses.
Materials and methods
Human subjects, specimens and controls
In accordance with approved Institutional Review Board
protocols, serum samples from patients with SLE were
obtained with informed consent from the Autoimmune
Biomarkers Collaborative Network (ABCoN), a multi-
disciplinary, multi-institutional effort to identify clini-
cally useful biomarkers for the management of autoim-
mune diseases [38-40]. Normal sera and neutrophils
were similarly obtained from healthy donors as part of
the Stanford Chronic Immunologic Disease Registry and
Repository and IRB protocol #17036, respectively.
Human neutrophils were isolated from peripheral blood
as previously described [34], using Percoll (GE Health-
care) density gradient separation. A mixture of commer-
cially available autoimmune sera with defined
reactivities was used as a positive control (ImmunoVi-
sion, Springdale, AR), and secondary antibody alone was
used as a negative control.
Mice and NET immunization protocol
All animal experiments were approved by, and per-
formed in compliance with, a protocol approved by the
Institutional Animal Care and Use Committee of Stan-
ford University. Female Balb/c mice 9 to 12 weeks of
age were obtained from the Jackson Laboratory (Bar
Harbor, ME). All mice used in this study were main-
tained under standard conditions at the Stanford Uni-
versity Research Animal Facility. NETs from the EPRO
cell line (derived by differentiation from EML cells)
were prepared as described below. NETs were prepared
and stored at a concentration of 10 μg/ml of which 200
μl was subcutaneously injected at each immunization.
Each treatment group included 3 mice, immunized
weekly over 4 weeks with NETs alone, or NETs com-
bined with murine cathelicidin-related antimicrobial
peptide (CRAMP) at a 5:1 w/w ratio to NETs [41]. Pro-
teinuria was assessed by dipstick analysis using Albustix
(Bayer, Pittsburgh, PA). Mouse serum samples were
obtained by saphenous vein bleeding immediately before
the first injection and once every 4 weeks after immuni-
zation for up to 12 weeks.
Cell culture and differentiation of neutrophils
Maintenance and differentiation of myeloid cell lines
into neutrophils were performed at 37°C and 5% carbon
dioxide as previously described [42]. Briefly, the human
promyelocyte HL-60 cell line was obtained from ATCC
(Manassas, VA; #CCL-240) and maintained in RPMI
1640 (Invitrogen, Carlsbad, CA) media supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
25 mM hydroxyethyl piperazineethanesulfonic acid
(HEPES) and 1X penicillin/streptomycin (P/S). Cells
were maintained at a density range of 1 × 105 to 8 ×
105 cells/ml for a maximum of 80 passages, and differ-
entiated for 3 days into neutrophils from a starting den-
sity of 3 × 105 cells/ml with a final concentration of 1
μM all-trans retinoic acid (ATRA; Sigma, St. Louis,
MO) + 1.25% dimethylsulfoxide (DMSO).
The murine multipotent cell line EML (Clone 1) was
obtained from ATCC (#CRL-11691) and maintained in
Iscoveís modified dulbeccoís medium (IMDM) media
(Invitrogen) supplemented with 20% horse serum
(Omega Scientific, Tarzana, CA), 2 mM L-glutamine, 1X
P/S, and 15% stem cell factor (SCF) containing condi-
tioned media (from BHK/MKL cell supernatants,
detailed below). EML cells were maintained in 6-well
plates at a density range of 1 × 105 to 5 × 105 cells/ml
and differentiated for two days by adding a final concen-
tration of 10 μM ATRA and 25 ng/ml recombinant
murine IL-3 (Peprotech, Rocky Hill, NJ). The cells were
further differentiated for one day with fresh media con-
taining a final concentration of 60 μM ATRA and 150
ng/ml recombinant murine IL-3. After washing the cells
twice with PBS, they were grown in IMDM media (Invi-
trogen) supplemented with 20% horse serum (Omega
Scientific), 1X P/S and 10% BHK/HM-5 conditioned
medium as a source of GM-CSF, for 9 days without
splitting cells. At this stage, EML cells had differentiated
into EPRO cells, which were maintained in this medium
at a density of 0.5 × 105 to 8 × 105 cells/ml. EPRO cells
were differentiated for 3 days into neutrophils from a
starting density of 3 × 105 cells/ml with a final concen-
tration of 10 μM ATRA.
The murine promyelocyte cell line MPRO [43] was
obtained from Dr. Tsai (University of Utah) and main-
tained at a density range of 0.5 × 105 to 1.0 × 106 cells
in IMDM media supplemented with 20% horse serum,
1X P/S, and 10% BHK/HM-5 conditioned medium as a
source of GM-CSF, and differentiated for 3 days into
neutrophils from a starting density of 3 × 105 cells/ml
with a final concentration of 10 μM ATRA.
Conditioned media
Growth factors required for EPRO (EML-derived) and
MPRO cultures were obtained using two secreting cell
lines (generous gifts from Dr. Tsai, University of Utah)
and prepared as previously described [42]. Briefly, baby
hamster kidney HM-5 (BHK/HM-5) cells, which secrete
murine GM-CSF, or baby hamster kidney MKL (BHK/
MKL) cells, which secrete murine SCF, were maintained
in DMEM high glucose media (Invitrogen) supplemen-
ted with 10% heat-inactivated FBS off US origin (Omega
Scientific), 2 mM L-glutamine, and 100 U/ml penicillin/
100 μg/ml streptomycin (1X P/S). These were expanded
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to T-175 flasks and grown to confluence. Cell culture
supernatants were harvested when the media turned yel-
low-orange, then sterile-filtered and frozen at -20°C
until ready for use.
Stimulation and isolation of NETs
Neutrophils derived from cell lines or isolated from
human donors were stimulated to produce NETs as pre-
viously described [2,34]. Neutrophils were incubated at
37°C with 5% carbon dioxide, in 100 mm plates (up to
10 ml volume) or 150 mm plates (10 to 40 ml volume)
at 1.5 × 106 cells/ml in serum-free RPMI media lacking
phenol red (Invitrogen) and stimulated with one of the
following stimulants at final concentration: 30 nM phor-
bol myristate acetate (PMA), 8 μM ionomycin, 10 mM
hydrogen peroxide, 7.0 ng/ml TNF (7.4 ng/ml for
EPRO), or 250 ng/ml lipopolysaccharide (LPS). At 2
hours (additionally, at 0 hours for primary human neu-
trophils), protease inhibitor cocktail (Sigma, #P1860)
was add at 1:200 dilution. After 2 to 3 more hours, cells
and NETs were detached with a cell scraper, transferred
to 15 ml or 50 ml conical tubes, and pelleted by spin-
ning at 1000 × g for 5 minutes. To gently digest the
NETs, the supernatant was discarded and the pellet
resuspended in micrococcal nuclease (MNase;
Worthington Biochemical, Lakewood, NJ) digestion mix-
ture containing 5 U/ml MNase and 10 mM calcium
chloride in 1X PBS (and additionally, protease inhibitor
cocktail for primary human neutrophils). This mixture
was gently pipetted until the pellet fully dissolved, typi-
cally in 30 seconds. The mixture was then further incu-
bated at 37°C in a heat block for 30 seconds, and
pelleted by centrifugation at 3000 × g for 1 minute. The
cleared supernatant was used as the chromatin fraction
in subsequent analyses.
Quantitation of NETs and apoptosis assays
An aliquot of NETs and of unstimulated neutrophils
(about 2 to 3 × 106 cell equivalents each) were sepa-
rately processed in parallel with the Qiagen DNeasy
Blood and Tissue kit (, Valencia, CA) following the
manufacturer’s instructions to obtain genomic DNA.
NET yield was determined with a Nanodrop 1,000 UV
spectrophotometer (NanoDrop, Wilmington, DE) and
calculated from the ratio of DNA obtained from NETs
relative to that obtained from the corresponding unsti-
mulated neutrophils. NET DNA prepared in this fashion
was also separated by electrophoresis on a 2% tris-acet-
ate-EDTA agarose gel with 0.3 μg/ml ethidium bromide
to ascertain the degree of NET digestion. Apoptosis
accompanying NETosis was measured by Caspase-Glo
chemiluminescent assay (Promega, Fitchburg WI) during
a 4-hour NET stimulation assay induced by hydrogen
peroxide within primary human neutrophils or HL-60
derived neutrophils. Staurosporine was used as a posi-
tive apoptosis control and was also compared with
untreated neutrophils resting over the same interval.
Fluorescence imaging of NETs
Indirect fluorescence of NETs using 4’,6-diamidino-2-
phenylindole (DAPI) stain was performed as described
in [44], using FBS heat-inactivated at 70°C for 30 min-
utes to avoid bovine serum nucleases from degrading
NETs [45]. Images were acquired using a Leica DM5000
microscope with a HCX PL Fluotar 40X/0.75 oil objec-
tive, using a QImaging Scientific Retiga EXi Fast 1394
digital capture camera with RGB Slider, with the QCap-
ture Pro Version 5.0 image capture software. Back-
ground color inversion was performed using Adobe
Photoshop Version 7.0.
Immunoblot profiling of NET post-translational
modifications
NETs were analyzed with a panel of 41 antibodies speci-
fic to both unmodified histones and histones modified
with various post-translational modifications (Additional
file 1: Supplemental Table 1), using a MABA based on
the Miniblotter apparatus (Immunetics, Cambridge,
MA) [37,46]. Unstimulated neutrophils were lysed in
RIPA buffer (150 mM sodium chloride, 1.0% NP-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), and 50 mM Tris-HCl, pH 8.0; supplemented with
a protease inhibitor Complete tablet (1 mini tablet per
10 ml; Roche, Basel, Switzerland) and sonicated for 20
seconds at 50% duty cycle (one second on, one second
off) and 13% amplitude with a digital sonifier (Branson,
Danbury, CT).
Sonicated cell lysates and digested NETs were each
combined with sample loading buffer (final concentra-
tion 2% SDS, 50 mM Tris-HCl pH 6.8, 6% glycerol, 1%
beta-mercaptoethanol and 0.008% bromophenol blue),
denatured at 100°C for 5 minutes, then separated in an
18% SDS-PAGE gel using a 2-D preparative gel comb
(one gel-width lane plus one small lane for protein mar-
ker). The gel was transferred onto a polyvinylidene
fluoride (PVDF) membrane (Millipore, Billerica, MA)
using a semi-dry transfer system, blocked with blotting-
grade blocker (Bio-Rad, Hercules, CA), washed in 1X
tris-buffered saline plus 0.1% tween (TBST).
The blocked and washed membrane was assembled in
a 28-lane Miniblotter apparatus following the manufac-
turer’s instructions. Up to 22 antibodies at the appropri-
ate dilution (Table S1) from the panel were applied, one
in each lane, with empty lanes applied with 1X TBST.
The apparatus was then sealed and the Miniblotter was
incubated at 4°C overnight on a rocking platform. The
Miniblotter was washed with 60 ml 1X TBST using its
vacuum manifold. The membrane was removed and
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washed once for 15 minutes in TBST, then 3 times for 5
minutes in TBST. A mixture of horse radish peroxidase
(HRP)-conjugated donkey anti-rabbit secondary antibody
and HRP-conjugated goat anti-mouse antibody (Jackson
Immunoresearch, West Grove, PA), each at 1:25,000
dilution in TBST, was applied to the membrane and
incubated for 1 hour. Following washes in TBST (15
minutes once, then 5 minutes for 3 times), enhanced
chemiluminescent (ECL) detection reagent (GE Health-
care) was applied, and the blot was developed on film.
Microarray autoantibody profiling
Detailed autoantibody profiling protocols and a list of
arrayed antigens have been published previously [35].
Briefly, autoantigens were printed in ordered arrays on
nitrocellulose-coated FAST slides (Whatman, Piscat-
away, NJ) at 0.2 mg/ml concentration using a Versarray
ChipWriter Pro Robotic Arrayer (Bio-Rad). Individual
arrays were blocked with 1% blocking-grade blocker
(Bio-Rad) in PBS for 1.25 hours on a rocking platform
at room temperature. Arrays were probed with 400 μl
human or mouse serum diluted 1:250 in 1X PBST with
5% FBS for 1.5 hours on a rocking platform at 4°C, fol-
lowed by washing and incubation with a 1:2000 dilution
of DyLight 649-conjugated goat anti-human or goat
anti-mouse IgG secondary antibody (Jackson Immunore-
search). Arrays were scanned using a GenePix 4000B
scanner, always using the same PMT power for a given
set of arrays. The net mean pixel intensities of each fea-
ture were determined using GenePix Pro 6.1 software
(Molecular Devices, Sunnyvale, CA). Epigenome peptide
microarrays were probed with mouse serum as
described [36]. All microarray data have been deposited
in the Gene Expression Omnibus (GEO) as GSE32544.
Statistical methods
Data were expressed as mean net fluorescence intensity
(MFI) units, representing the mean values from six
replicate antigen or peptide features on each array. His-
tone-reactive SLE samples were defined as having a
minimum normalized IgG MFI of 10,000 in at least one
whole-protein histone antigen and histone-nonreactive
samples were defined as having a maximum normalized
IgG MFI less than 1,000 in any whole-protein histone
antigen. Significance Analysis of Microarrays (SAM) [47]
was applied to the dataset (with the MFI value of unde-
tected array features set to 1) using the Wilcoxon
signed-rank test statistic to identify antigens with statis-
tically significant differences in array reactivity between
different groups of human patients at False Discovery
Rate of 0. Datasets were hierarchically clustered using
Cluster 3.0 [48], using Euclidean distance and average
linkage, with the MFI value of undetected array features
set to 0 and with positive control samples excluded
from being weighted in the clustering process. Results
were displayed using Java TreeView software [49]. Sig-
nificance of overlap between mouse IgM and IgG auto-
antigen reactivity was determined using cumulative
hypergeometric distribution with a total population size
of 122 antigens and an overlap of 28 to 36. The Eucli-
dean distance between IgM and IgG profiles was calcu-
lated from their MFI values, with nominal P-value
determined using a paired two-tailed t test.
Results
Distinctive profiles of SLE sera with and without reactivity
toward histones
To test the hypothesis that NETs and the histone PTMs
that they harbor might be capable of inducing anti-his-
tone autoantibodies, we first tested serum samples from
the ABCoN, a well-studied cohort of adult patients with
SLE [38-40]. We randomly selected serum samples of 20
patients from a larger cohort profiled using autoantigen
microarrays (data not shown), comprising 14 histone-
reactive samples and 6 histone-nonreactive samples.
Using the Human Epigenome Microarray Platform
(HEMP) [36], we compared these SLE sera to each
other as well as to control sera from nine healthy adults
and to a positive control comprising a mixture of auto-
immune sera with defined reactivity.
Using SAM, we identified IgG reactivity to nine pep-
tides that significantly distinguish histone-reactive from
-nonreactive sera among 96 peptides profiled (False Dis-
covery Rate = 0). These reactivities included 5 of 41
peptides for which specific, commercially-available anti-
bodies were tested (Figure 1), as well as 4 others (that
is, H2BK15Ac, H3K18Me3K36Me3, H2BK5Me1, and
H2BK5Me2). Hierarchical clustering of serum samples
resulted in grouping of most of the histone-reactive
sera, along with the positive control, with the clustering
driven by reactivity to unmodified histone H2B peptide
as well as H2B peptides acetylated at K12 and K20. Col-
lectively, these findings are consistent with a previously
published study reporting SLE autoantibody reactivity to
apoptosis-related acetyl-H2B epitopes [28].
IgM autoantibody profiles exhibited similar reactivity
patterns in the mixed PTM peptide panel (Additional
file 1: Supplemental Figure 1, right panel), including
acetyl peptides of histones H2B, H3 and H4, again con-
sistent with prior studies [28,29]. We also observed con-
siderable reactivity to multiple methyl-histone H3
peptides (Additional file 1: Supplemental Figure 1, left
panel). However, both histone reactive and healthy sera
shared this reactivity pattern and thus were not deter-
mined to be significant by SAM. Given that IgM antibo-
dies tend to be lower affinity with broader cross-
reactivity and may occur naturally with potential regula-
tory and protective roles against autoimmunity [50], the
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significance of reactivity among these epitopes is less
clear. Modest levels of IgG or IgM reactivity to citrulli-
nated H3 and H4 peptides were also observed, with no
significant difference between SLE and healthy sample
groups.
Efficient production and visualization of NETs in vitro
We next devised methods for generating NETs from
human and murine myeloid cell lines, to facilitate the
broad and uniform characterization of PTMs on human
and murine NETs and to provide a supply of NETs for
testing their immunogenicity in vivo (Figure 2). We
employed two sources of murine and two sources of
human NETs, including two murine cell lines derived
from cells arrested in early myeloid differentiation
(MPRO/promyelocyte; EML/multipotent progenitor),
the human promyelocytic leukemia cell line HL60 as
well as mature human granulocytes from healthy adult
donors. To culture and differentiate the three immature
cell lines into neutrophils, we adapted previous methods
[34,42,44] then stimulated them as well as primary
human neutrophils to produce NETs using hydrogen
peroxide, TNF and LPS. We then visualized the result-
ing NETs using fluorescence microscopy (Figure 2). The
corresponding NET DNA was characterized by gel elec-
trophoresis (Additional file 1: Supplemental Figure 2)
and the NET DNA yield from these diverse sources was
quantified (Additional file 1: Supplemental Table 1). The
DNA yield of purified NETs relative to unstimulated
neutrophils varied depending on the preparation source
and type of stimulus used for NETosis, ranging from <
10% for MPRO, 15% to 50% for EPRO (differentiated
from EML cells), 9% to 45% for HL-60 and > 70% for
primary human neutrophils. Importantly, we found that
induction of NETosis in HL-60 cells and primary
human neutrophils did not result in a significant degree
of apoptosis (Additional file 1: Supplemental Figure 3).
Post-translational modification profiles of human and
murine NETs
To assess the immunogenicity of NETs in the context of
autoantibody binding reactivity profiles observed (Figure
1), we biochemically characterized the PTMs present on
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Figure 1 Histone-reactive SLE IgG autoantibodies recognize acetyl-H2B. Sera from patients with SLE or healthy subjects were profiled on
Human Epigenome Microarray Platform (HEMP) and probed with a secondary anti-human IgG antibody. Samples (rows) are clustered
hierarchically based on corresponding reactivity profiles to the depicted peptide epitopes from HEMP arrays (columns). The depicted histone
peptides (columns) were selected to match those interrogated by immunoblot assays in Figure 4 and Additional file 1: Supplemental Figures 2
and 4, with specific PTMs epitopes shown at top according to the PTM key. Heatmap tiles reflect magnitude of IgG autoantibody binding
reactivity, according to the mean fluorescence intensity (MFI) intensity scale as indicated. The left heatmap panel consists primarily of peptides
containing mono-, di- and tri-methyl lysine PTMs, while the right panel consists of peptides containing a variety of PTMs, including citrulline,
acetyl, phosphoryl, and both symmetric (s) and asymmetric (a) di-methyl arginine. Blue asterisks (*) mark significant differences in autoantibody
binding reactivity between histone positive samples and a combined group of histone negative and healthy control samples, as determined by
Significance Analysis of Microarrays (SAM). IgG, immunoglobulin G; K, lysine; MFI, mean fluorescence intensity; nd, not detected; PTM, post-
translational modification; R, arginine; SLE, systemic lupus erythematosus.
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assay (modified MABA [37]) that allows such profiling
in a parallel manner using a MiniBlotter apparatus dur-
ing primary antibody incubation. A set of 22 commer-
cially available PTM-specific anti-histone antibodies was
used to probe each immunoblot membrane, with a total
of 44 epitopes (41 unique; Additional file 1:
Supplemental Table 2) profiled in two separate panels.
The two panels comprised one for profiling histone tail
methylation (Additional file 1: Supplemental Figure 4A)
and a second for capturing a variety of other histone
PTMs (Additional file 1: Supplemental Figure 4B). We





















Figure 2 Generation and visualization of neutrophil extracellular traps (NETs) from myeloid cell lines and human primary neutrophils.
A. Three cell line models used to generate neutrophils and NETs. Murine cell lines EPRO and MPRO were induced with ATRA and GM-CSF to
differentiate into neutrophils. EPRO cells were generated by differentiating the EML multipotent progenitor cell line with ATRA, GM-CSF and IL-3.
NETs were generated by stimulating cell line-derived or primary human neutrophils with hydrogen peroxide. B. Fluorescent (DAPI) images of
NETs produced from neutrophils derived from EPRO, HL-60 or MPRO cell lines, or from primary human neutrophils. Color channels are inverted
to yield white background for improved contrast. 400× magnification. ATRA, all-trans retinoic acid; DAPI, 4’,6-diamidino-2-phenylindole; DMSO,
dimethyl sulfoxide; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-3, interleukin-3.
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dependent on the conditions of each experiment, since
the production of NETs coincides with neutrophil pro-
tease release.
We next compared chromatin preparations from pri-
mary human neutrophils and unstimulated HL-60
derived neutrophils to NETs derived from these same
neutrophils following stimulation with hydrogen perox-
ide (Figure 3 and Additional file 1: Supplemental Figure
4). HL-60 derived neutrophils were also separately sti-
mulated with TNF or LPS to induce NETs (Additional
file 1: Supplemental Figure 4). During NETosis of pri-
mary human PMNs we observed significant proteolysis
of the core histone proteins, limiting the availability of
many histone PTMs (data not shown), as has been pre-
viously reported [34]. Therefore, for primary human
PMNs, we used a more limited PTM panel selected on
the basis of epitopes whose states were observed to be
different in NETs compared to unstimulated neutrophils
derived from cell lines and not subject to degradation.
NETs derived from primary human neutrophils were
enriched for several histone PTM methylation, citrulli-
nation and acetylation marks, including H4K20Me1/2/3,
H3Cit(2,18,17), H4Cit3, H4K5Ac, and H4K16Ac, while
depleted for H3K9Ac.
For comparison, HL-60 NETs were depleted of several
PTMs associated with active transcription including
H3K27Ac, H3K36Me2, H2BK12Ac, and H3K9Ac (Addi-
tional file 1: Supplemental Figure 4), and conversely,
enriched for PTM marks associated with transcriptional
inactivation during NETosis, including mono-, di- and
tri-methyl H3K27. Further, levels of di-methyl arginine
modification also decreased to nearly undetectable levels
in HL-60 derived NETs, consistent with deimination of
the arginine to citrulline during NETosis. Unexpectedly,
however, we observed a moderate decrease in histone
H3 citrullination during NETosis of HL-60 derived neu-
trophils, distinguishing them from primary human
PMNs which induced a strong citrullination signature
upon NETosis. Since we observed hypercitrullination in
NETs derived from primary human neutrophils, our
HL-60 population could conceivably harbor genotypic
or phenotypic differences from HL-60 cells character-
ized in previous reports [31,32], accounting for the dis-
cordance with previously published observations.
In comparing the PTMs found in human NETs to epi-
topes recognized by serum autoantibodies from patients
with SLE, many but not all autoantibody-reactive PTMs
of SLE were also found in NETs. For example, while
acetyl-H3 at K14 and K18 were recognized by serum
IgG autoantibodies and also detected in NETs, acetyl-
H3K9 and dimethyl-H4R3 (symmetric) were recognized
but were only weakly positive or not detected in NETs
derived from HL-60 cells. Many PTMs present in NETs
(for example, other acetyl-H3; acetyl-H4) only exhibited
modest IgG serum reactivity, which was present in both
healthy controls and SLE patients. Serum IgM reactivity
(Additional file 1: Supplemental Figure 1, left panel) was
more widespread and thus overlapped to a greater
extent with PTMs detected in NETs (many methyl-H3
PTMs, Additional file 1: Supplemental Figure 4). How-
ever, we observed this pattern both in patients with SLE
known to have IgG histone auto-reactivity and healthy
subjects, indicating that these observed IgM reactivities
may not be indicative of a disease state.
Next, we biochemically characterized the PTMs pre-
sent on EPRO-derived murine NETs with a goal of test-
ing their immunogenicity in vivo. EPRO-derived NETs
were prepared as for human cells described earlier and
subjected to ionomycin and phorbol myristate acetate
(PMA) as two additional stimuli (Figure 4). When com-
paring HL-60 and EPRO-derived NETs, the majority of
the histone PTMs were consistent during NETosis and
also similar in response to diverse stimuli. Specifically,
in comparing EPRO-derived NETs to corresponding
unstimulated neutrophils, we observed an even more
striking pattern of PTMs associated with a transcription-
ally silent state than for HL-60 cells. Furthermore, we
observed an increase in the silencing marks di-methyl
H3K9 and tri-methyl H4K20. In contrast with HL-60
derived NETs, however, we observed a strong citrullina-
tion signature (Figure 4B) in NETs prepared from
EPRO-derived neutrophils, clearly demonstrating abun-
dant citrullination of histones H3 and H4 and consistent
with previous studies and primary human PMNs.
Figure 3 Post-translational histone modifications of neutrophil
extracellular traps (NETs) derived from primary human
neutrophils. Primary human neutrophils were isolated from
peripheral blood, immediately stimulated with 10 mM hydrogen
peroxide for 4 hours, and NETs were harvested. NETs or the
corresponding unstimulated neutrophils were assayed by MABA. A
panel of anti-histone antibody epitopes (top) is shown, with PTMs
according to the PTM key. A more limited PTM panel was selected on
the basis of available epitopes not subject to proteolysis by
considering those enriched or depleted during NETosis of neutrophils
derived from human and murine cell lines (Figure 4 and Additional file
1: Supplemental Figure 4). Bottom: asterisks or carats indicate increase
or decrease (respectively) of band intensity for indicated lane in NETs
compared to unstimulated neutrophils. Band migration is shown for
10-15 kDa range and film exposure time was 20’. MABA, Multiple
Antigen Blot Assay; PTM, post translational modification.
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Murine NETs are weakly immunogenic in vivo
We next tested the immunogenicity of NETs derived
from the murine EPRO cell line in vivo. NETs prepared
using hydrogen peroxide stimulation of EPRO cells were
subcutaneously injected into two groups of female
BALB/c wild-type mice weekly over 28 days, with one
group receiving NETs alone, and another receiving
NETs in combination with CRAMP, the murine analo-
gue of LL-37 [41]. Trace or low levels of urinary protein
were measured during the remainder of the time course,
suggesting a weak response to the NET immunization
(Additional file 1: Supplemental Table 3). Autoantibody
profiles reflected reproducible and time-dependent
responses for IgG and IgM and targeted diverse auto-
antigens (n = 36 and n = 38, respectively; Additional file
1: Supplemental Figure 5A-C), although these responses
were modest and transient. Reactivity to 28 antigens was
observed for both IgG and IgM isotypes (P = 1.88 × 10-
12), including many components within neutrophils or
NETs, such as myeloperoxidase, catalase, histones
(including H1 and H3), as well as single and double-
stranded DNA. Nonetheless, mice immunized with
NETs showed significant differential IgM and IgG reac-
tivity towards many of the same antigens, as well as
others (Additional file 1: Supplemental Figure 5D).
Furthermore, we observed reproducible IgG seroreactiv-
ity targeting human IgG in mice immunized with NETs
derived in serum free conditions, possibly reflecting a
species cross-reactive rheumatoid factor activity precipi-
tated by citrullinated murine NETs. Taken together, the
autoantibody reactivity profiles are consistent with the
antigenic components of the NET immunogen but sug-
gest a modest response to common lupus autoantigens.
Autoreactivity profiles of PTM-specific histone pep-
tides from the HEMP arrays revealed a transient IgG
response in one individual mouse that disappeared by the
third month and very little reactivity in the other two
mice (Additional file 1: Supplemental Figure 5E). There
was little or no reactivity to adjuvanted CRAMP or its
human analogue, LL-37. Interestingly, all three mice and
the MRL/lpr positive control serum exhibited strong IgM
and IgG autoreactivity to methyl-H3K18, which
decreased somewhat at the three month time point.
Methyl-H3K18 is a recently identified methylation mark
on histone H3 and has been previously reported to be
expressed at reduced levels in MRL/lpr splenocytes [51].
Therefore, the targets of autoreactivity observed in SLE
and induced by NET immunization overlap partially,
with several PTMs distinguishing NET-induced autoreac-
tivity from SLE-autoreactivity profiles.
Discussion
Since their recent discovery, NETs have been the focus
of considerable study examining their roles in innate
immunity, and in particular, assessing several putative
links to autoimmunity. Histone proteins which are a
Figure 4 EPRO-derived neutrophil extracellular traps (NETs) contain histone post translational modification (PTM) marks consistent
with transcriptional silencing and hypercitrullination. Murine cell-line derived neutrophils were stimulated and analyzed as in Figure 3 with
additional stimulants including ionomycin and PMA. A panel of anti-histone antibody epitopes (top) matching those in Additional file 1: Supplemental
Figure 4 is shown, with PTMs according to the PTM key. A strong and saturated band is notable with H3Cit(2,8,17) in EPRO NETs. Film exposure time
for all cells were as described in Figure 3 (additional stimulants: 2’ for ionomycin and 90’ for PMA). PMA, phorbol myristate acetate.
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significant component of NETs, have long been the sub-
ject of intense study as they comprise a major class of
autoantigens in SLE [52] and are richly decorated with
PTMs that dynamically encode epigenetic information
in chromatin [53]. However, few studies have character-
ized the post-translational state of histones within NETs
or examined their association with autoimmunity. We
tested the hypothesis that NETs and histone PTMs have
the capacity to induce autoantibodies that target his-
tones with a focus on SLE.
First, we asked whether histone PTM-specific reactiv-
ity could be identified and characterized in SLE, in
order to serve as a basis of comparison for any histone
PTMs identified in NETs. In comprehensive autoanti-
body profiling of a well-characterized cohort of patients
with SLE within the ABCoN on human epigenome
microarrays, we confirmed serum IgG reactivity to
acetyl-histone H2B peptides in concordance with pre-
vious work [28]. We also observed statistically signifi-
cant IgM reactivity to multiple H3 and H4 PTM
epitopes as well as widespread serum IgM reactivity to
methyl-H3 PTM epitopes. One possible explanation is
that endogenous histone PTMs may induce a low-level
autoantibody response that is present in both healthy
and SLE patients and that additional pro-inflammatory
signals and T cells help are required to induce autoreac-
tive B cells to affinity maturation and isotype switching
to IgG [54]. Surprisingly, serum reactivity to citrulli-
nated epitopes was observed at only low levels for both
IgM and IgG. The biological and clinical significance of
these findings will require additional and ongoing
studies.
To ascertain whether NETs contain SLE serum-reac-
tive PTM antigens, we characterized human and mur-
ine-derived NETs using a broad panel of unique,
commercially available antibodies recognizing specific
histone PTMs. We observed that histones within NETs
harbored most of the examined methylation marks,
including mono-, di-, and tri-methyl H3 at K4, K9, K27,
K36 and H4 at K20. Separately, we identified major
trends in the pattern of other histone PTMs enriched in
NETs derived from activation of neutrophils using
diverse stimuli, including marks associated with tran-
scriptional repression as well as hypercitrullination. This
suggests that examining the PTM state of NET chroma-
tin may yield insights into the underlying mechanisms
responsible for the profound changes to the chromatin
during the process of NETosis.
The hypercitrullination that we observed during
NETosis in primary human PMNs and EPRO cells sti-
mulated with diverse stimuli confirms an earlier report
of citrullination in HL-60 cell-derived NETs [55]. Con-
sistent with this finding, we observed a corresponding
decrease in arginine methylation during NETosis of
human and mouse neutrophils, likely reflecting conver-
sion of arginine residues to citrulline. Other, more
subtle differences were observed in multiple marks
across different conditions; however, given the ECL
amplification approach used in most standard immuno-
blotting approaches, along with the performance of
most commercial polyclonal antibodies, it is difficult to
ascertain whether such differences are biologically
significant.
However, many but not all PTMs that were recog-
nized by serum autoantibodies from SLE patients were
found in NETs. Many of the serum-reactive PTMs
found in NETs were detected at only modest levels in
both SLE histone positive and healthy serum samples,
for both IgG and IgM isotypes. Surprisingly, histone
PTMs toward which significantly more reactivity was
observed in sera from SLE patients known to have anti-
histone antibodies (in particular, acetyl-H2B), were
absent or detected at only low levels in NETs produced
from HL-60 or EPRO cells.
To account for this discordance, one possibility may
be that acetylated histones are dissociated during the
chromatin condensation step in NETosis-acetylated his-
tones are thought to be in a looser conformation within
the nucleosome due to loss of positive charge on acetyl
lysine residues [56]. It is also conceivable that these
acetyl histones may be particularly immunogenic since
they may disperse more widely, increasing their chances
of uptake by a professional antigen presenting cell, gen-
erating a subsequent proinflammatory response by the
adaptive immune system. A second possibility is that
only the NETs from a special subpopulation of polymor-
phonuclear cells are responsible for their immunogeni-
city in SLE. A recent study described the discovery of
low density granulocytes (LDGs) whose greater tendency
to undergo NETosis elicited a stronger immune
response than conventional neutrophils [57].
Numerous studies have investigated the significance of
histone acetylation in SLE, and the pattern of evidence
suggests that histone acetylation within cells negatively
correlates with disease activity. Splenocytes from MRL/
lpr mice have hypoacetylated histones H3 and H4 when
compared to control MRL/MPJ mice [51] and adminis-
tration of trichostatin A (a histone deacetylase (HDAC)
inhibitor) to MRL/lpr mice can be used to improve dis-
ease outcome [51,58]. In T cells isolated from SLE
patients, global H3 and H4 hypoacetylation was
observed when compared to cells obtained from healthy
donors [59]. Furthermore, mice with a conditional
knock-in of the p300 acetyltransferase gene (in which
the histone acetyltransferase activity was absent) develop
spontaneous lupus-like disease [60]. Collectively, these
studies demonstrate that hypoacetylated histones are
associated with increased disease activity and that
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interventions restoring acetylation in MRL/lpr mice
improved disease outcome.
Clearly, the acetylation state of histones in disease-
relevant cells has a significant bearing on disease out-
come; the discordance between observed anti-acetyl his-
tone antibodies in SLE sera and the decrease in acetyl
histones in NETs suggest the following three possibili-
ties: (i) NETs are depleted of acetylated histones during
NETosis and that these free histones may contribute to
the autoimmune response in SLE; (ii) NETs are not the
in vivo immunogens responsible for the observed pat-
terns in reactivity to histone PTMs; and (iii) NETs
derived from LDGs are enriched for acetyl histones and
may account for their increased immunogenicity.
In our own mouse studies, we immunized BALB/c
mice with NETs or with NETs combined with CRAMP
and expected the mice to develop autoantibodies that
recognize specific PTMs present in NETs. Here, we
tested the hypothesis that NET PTMs are capable of
breaking tolerance to self-antigens, including but not
limited to histone PTMs, as observed in human SLE.
We observed a moderately strong IgM and IgG response
to DNA and a modest response to other NET self-anti-
gens, including myeloperoxidase, elastase, and histones.
This result is similar to mouse studies performed by
Mevorach et al. in which mice were immunized with
material derived from apoptotic cells, leading to a mod-
est, transient response including the production of anti-
nuclear antibodies, anticardiolipin and anti-dsDNA
antibodies, along with increased glomerular IgG deposi-
tion [22] and slightly accelerated disease kinetics in
MRL/lpr and other autoimmune backgrounds [61].
However, while we observed modest but significant and
reproducible IgG and IgM reactivity to self-antigens,
these mice did not exhibit other features of human SLE
nor of autoimmune-prone SLE mouse models. One pos-
sible explanation for this observation is that NET chro-
matin purified in vitro is not equivalent to NETs
generated in vivo, since the latter includes microbial
determinants associated with TLR ligands and could
thus act as superior adjuvants to break tolerance to self-
antigens.
Anti-histone antibodies have also been observed in
other diseases. For instance, NETs have been observed
in the glomeruli of patients with antineutrophil cytoplas-
mic antibodies (ANCA) associated vasculitis, perhaps
reflecting a common etiology [62]. In drug-induced
lupus (DIL), the vast majority of patients exhibit signifi-
cant positive anti-histone antibody titers primarily tar-
geting histone H2A/H2B [63], concordant with our
observed significant reactivity to acetyl and unmodified
histone H2B. Extracellular histones can induce septic
shock in mice and concurrent infusion of anti-histone
H4 antibodies was protective against LPS-induced shock
[64]. This finding is consistent with speculation in the
field that IgM autoantibodies may play a protective role
against an excessive immune response [50]. We evalu-
ated the role of distinctive NET PTMs as a source of
self-antigens with a qualitative relationship to autoim-
munity. However, a clearance deficiency of NETs has
also been described in patients with SLE [4]. Therefore,
persistence of NETs, through insufficient clearance by
endonucleases or phagocytes, may serve as a comple-
mentary quantitative perturbation leading to SLE
pathogenesis.
Nucleoprotein complexes are also candidates to be
involved in both the etiology and pathogenesis of SLE
and murine lupus, wherein they might complement
NETs. Many dsDNA autoantibody-producing B cells
from SLE patients are thought to be affinity selected by
uncleared apoptotic lymphocytes in germinal centers.
Therefore, it may not be surprising that NET derived
modifications are not the dominant epitopes recognized
by anti-histone autoantibodies. Further, in the presence
of anti-dsDNA, NETs generated in several tissues may
serve as targets for the anti-dsDNA. The binary complex
of nucleoprotein and autoantibody may be prone to shift
the clearance of dead cell remnants (apoptotic bodies
and NET-structures) to inflammation.
Many of the specific post-translational histone modifi-
cations enriched in NETs overlapped those to which sig-
nificant autoreactivity is seen in a subset of patients with
SLE. Nonetheless, this overlap was partial, and many
PTMs distinguished NETs from SLE-autoreactivity pro-
files. Further, while NETs were observed to be modestly
immunogenic in vivo, the induced serological autoim-
mune responses were distinct from those observed in
patients with lupus, as well as autoimmune-prone MRL/
lpr mice.
Conclusions
In summary, to investigate the link between NETs and
SLE, using histone PTMs as prospective biomarkers, we
investigated the serum reactivity profile to a panel of
histone PTMs in a cohort of SLE patients and identified
significant autoantibody reactivity to acetyl-histone H2B.
We devised a methodology to culture myeloid cell lines
to produce NETs, and found that their PTMs indicate a
state of transcriptionally silent chromatin that has
decondensed with the aid of citrullination, a result of
the NETosis process. Some of the human SLE serum
reactivity overlaps with PTMs found on NETs; however,
the presence of autoantibodies against acetyl-histone
H2B is discordant with the decrease in histone H2B
acetylation in NETs. Furthermore, murine cell line-
derived NETs are weak immunogens in vivo. This result
suggests that the breaking of tolerance to self requires
more than a simple exposure to NETs.
Liu et al. Arthritis Research & Therapy 2012, 14:R25
http://arthritis-research.com/content/14/1/R25
Page 11 of 14
Additional material
Additional file 1: Supplementary Appendix. Supplementary
information containing Supplemental Tables 1-3 and Supplemental
Figures 1-5.
Abbreviations
ABCoN: Autoimmune Biomarkers Collaborative Network; ANCA:
antineutrophil cytoplasmic antibody; ATCC: American Type Culture
Collection; ATRA: all-trans retinoic acid; CRAMP: cathelicidin-related
antimicrobial peptide; DMSO: dimethylsulfoxide; FBS: fetal bovine serum;
GM-CSF: granulocyte macrophage colony-stimulating factor; HDAC: histone
deacetylase; HEMP: human epigenome microarray platform; HRP: horse
radish peroxidase; Ig: immunoglobulin; IL-3: interleukin 3; IMBM: Iscoveís
modified dulbeccoís medium; IRB: Institutional Review Board; LDG: low
density granulocyte; LPS: lipopolysaccharide; MABA: Multiple Antigen Blot
Assay; MFI: mean fluorescence intensity; MNase: micrococcal nuclease; NET:
neutrophil extracellular trap; P/S: penicillin/streptomycin; PAD: peptidyl
arginine deiminase; PBST: phosphate-buffered saline and tween; pDC:
plasmacytoid dendritic cell; PMA: phorbol myristate acetate; PTM: post-
translational modification; RA: rheumatoid arthritis; SAM: Significance Analysis
of Microarrays; SCF: stem cell factor; SLE: systemic lupus erythematosus; SR:
serine/arginine-rich; TBST: tris-buffered saline and tween; TLR9: Toll-like
receptor 9; TNF: tumor necrosis factor.
Acknowledgements
This work was supported in part by grants from the NIH to PJU (5 U19-
AI082719, G. Fathman as primary investigator), from the NIH to OG (R01
GM079641), by the National Heart, Lung, and Blood Institute Proteomics
contract (HHSN288201000034C, G. Nolan as primary investigator), by the
Canadian Institute of Health Research grant to PJU (2 OR-92141), by the
European Commission FP Grant #261382 to PJU, and by a gift of the Floren
Family Trust to PJU. This publication was made possible by T32 AR050942
from NIAMS/NIH to CLL. CLL is a recipient of an NIH National Research
Service Award Fellowship (AI-080086-02). AAA is a Special Fellow of the
Leukemia & Lymphoma Society and recipient of a Doris Duke Clinician
Scientist Development Award. OG is a recipient of an Ellison Senior Scholar
in Aging Award.
Author details
1Department of Medicine, Division of Immunology and Rheumatology,
Stanford School of Medicine, 269 Campus Drive, Stanford, California 94305,
USA. 2Center for Immunology, University of Minnesota Medical School, 420
Delaware Street SE, Minneapolis, Minnesota, 55455, USA. 3Department of
Medicine, Division of Oncology and of Hematology, Stanford School of
Medicine, 300 Pasteur Drive, Stanford, California 94305, USA. 4Department of
Biology, Stanford University, 371 Serra Mall, Stanford, CA 94305, USA.
Authors’ contributions
CLL conceived of the study, designed and coordinated its execution, carried
out the immunoblot assays, performed statistical analysis for the array
studies, and drafted the manuscript. ST carried out array assays, cell culture,
NETs visualization, and mouse studies. JR participated in NETs visualization.
GM participated in cell culture and immunoblot assays. OG provided the
histone peptide libraries used in HEMP and immunoblot resources, including
the antibody panels. ECG provided human SLE samples used in this study.
AAA helped to design the experiments, to interpret and analyze resulting
data and to write the manuscript. PJU participated in the conception of the
study, participated in its design and coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests related to the
publication of this manuscript.
Received: 10 August 2012 Revised: 22 January 2012
Accepted: 2 February 2012 Published: 2 February 2012
References
1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS,
Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria.
Science 2004, 303:1532-1535.
2. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y,
Brinkmann V, Zychlinsky A: Novel cell death program leads to neutrophil
extracellular traps. J Cell Biol 2007, 176:231-241.
3. Baker VS, Imade GE, Molta NB, Tawde P, Pam SD, Obadofin MO, Sagay SA,
Egah DZ, Iya D, Afolabi BB, Baker M, Ford K, Ford R, Roux KH, Keller TC:
Cytokine-associated neutrophil extracellular traps and antinuclear
antibodies in Plasmodium falciparum infected children under six years
of age. Malar J 2008, 7:41.
4. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V,
Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular
trap degradation is associated with lupus nephritis. Proc Nat Acad Sci
USA 2010, 107:9813-9818.
5. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M,
Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V: Netting
neutrophils are major inducers of type I IFN production in pediatric
systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
6. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S,
Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T,
Liu YJ, Gilliet M: Neutrophils activate plasmacytoid dendritic cells by
releasing self-DNA-peptide complexes in systemic lupus erythematosus.
Sci Transl Med 2011, 3:73ra19.
7. Yung RL, Johnson KJ, Richardson BC: New concepts in the pathogenesis
of drug-induced lupus. Lab invest 1995, 73:746-759.
8. Hess E: Drug-Related Lupus. N Eng J Med 1988, 318:1460-1462.
9. Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P, Doménech I,
Aydintug A, Jedryka-Góral A, de Ramón E: Systemic lupus erythematosus:
clinical and immunologic patterns of disease expression in a cohort of
1,000 patients. The European Working Party on Systemic Lupus
Erythematosus. Medicine 1993, 72:113-124.
10. Schett G, Smolen J, Zimmermann C, Hiesberger H, Hoefler E, Fournel S,
Muller S, Rubin R, Steiner G: The autoimmune response to chromatin
antigens in systemic lupus erythematosus: autoantibodies against
histone H1 are a highly specific marker for SLE associated with
increased disease activity. Lupus 2002, 11:704-715.
11. Burlingame RW, Rubin RL: Drug-induced anti-histone autoantibodies
display two patterns of reactivity with substructures of chromatin. J Clin
Invest 1991, 88:680-690.
12. Rubin RL, Bell SA, Burlingame RW: Autoantibodies associated with lupus
induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA
complex. The Journal of Clinical Investigation 1992, 90:165-173.
13. Totoritis MC, Tan EM, McNally EM, Rubin RL: Association of antibody to
histone complex H2A-H2B with symptomatic procainamide-induced
lupus. N Eng J Med 1988, 318:1431-1436.
14. Clark DWJ: Genetically determined variability in acetylation and
oxidation therapeutic implications. Drugs 1985, 29:342-375.
15. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA: Effect of
acetylator phenotype on the rate at which procainamide induces
antinuclear antibodies and the Lupus Syndrome. N Eng Jf Med 1978,
298:1157-1159.
16. Jiang X, Khursigara G, Rubin R: Transformation of lupus-inducing drugs to
cytotoxic products by activated neutrophils. Science 1994, 266:810-813.
17. Utz PJ, Anderson P: Posttranslational protein modifications, apoptosis,
and the bypass of tolerance to autoantigens. Arthritis Rheum 1998,
41:1152-1160.
18. Satoh M, Kumar A, Kanwar YS, Reeves WH: Anti-nuclear antibody
production and immune-complex glomerulonephritis in BALB/c mice
treated with pristane. Proc Natl Acad Sci USA 1995, 92:10934-10938.
19. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic
lupus erythematosus are clustered in two populations of surface
structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
20. Rosen A, Casciola-Rosen L: Autoantigens as substrates for apoptotic
proteases: implications for the pathogenesis of systemic autoimmune
disease. Cell Death Differ 1999, 6:6-12.
21. Greidinger EL, Casciola-Rosen L, Morris SM, Hoffman RW, Rosen A:
Autoantibody recognition of distinctly modified forms of the U1-70-kd
antigen is associated with different clinical disease manifestations.
Arthritis Rheum 2000, 43:881-888.
Liu et al. Arthritis Research & Therapy 2012, 14:R25
http://arthritis-research.com/content/14/1/R25
Page 12 of 14
22. Mevorach D, Zhou JL, Song X, Elkon KB: Systemic exposure to irradiated
apoptotic cells induces autoantibody production. J Exp Med 1998,
188:387-392.
23. Gensler TJ, Hottelet M, Zhang C, Schlossman S, Anderson P, Utz PJ:
Monoclonal antibodies derived from BALB/c mice immunized with
apoptotic Jurkat T cells recognize known autoantigens. J Autoimmun
2001, 16:59-69.
24. Kamachi M, Le TM, Kim SJ, Geiger ME, Anderson P, Utz PJ: Human
autoimmune sera as molecular probes for the identification of an
autoantigen kinase signaling pathway. J Exp Med 2002, 196:1213-1225.
25. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB: SR proteins are
autoantigens in patients with systemic lupus erythematosus. Importance
of phosphoepitopes. Arthritis Rheum 2000, 43:1768-1778.
26. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM,
Hueber W, Robinson WH, Cairns E: Arthritis induced by posttranslationally
modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med
2008, 205:967-979.
27. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van
Venrooij WJ: Citrulline is an essential constituent of antigenic
determinants recognized by rheumatoid arthritis-specific autoantibodies.
J Clin Invest 1998, 101:273-281.
28. van Bavel CC, Dieker J, Muller S, Briand JP, Monestier M, Berden JH, van der
Vlag J: Apoptosis-associated acetylation on histone H2B is an epitope for
lupus autoantibodies. Mol Immunol 2009, 47:511-516.
29. Dieker JW, Fransen JH, van Bavel CC, Briand JP, Jacobs CW, Muller S,
Berden JH, van der Vlag J: Apoptosis-induced acetylation of histones is
pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007,
56:1921-1933.
30. van Bavel CC, Dieker JW, Kroeze Y, Tamboer WP, Voll R, Muller S, Berden JH,
van der Vlag J: Apoptosis-induced histone H3 methylation is targeted by
autoantibodies in systemic lupus erythematosus. Ann Rheum Dis 2011,
70:201-207.
31. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L,
Han H, Grigoryev SA, Allis CD, Coonrod SA: Histone hypercitrullination
mediates chromatin decondensation and neutrophil extracellular trap
formation. J Cell Biol 2009, 184:205-213.
32. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS,
McDonald CH, Cook RG, Dou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD,
Coonrod SA: Human PAD4 regulates histone arginine methylation levels
via demethylimination. Science 2004, 306:279-283.
33. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y: PAD4 is essential
for antibacterial innate immunity mediated by neutrophil extracellular
traps. J Exp Med 2010, 207:1853-1862.
34. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W,
Brinkmann V, Jungblut PR, Zychlinsky A: Neutrophil extracellular traps
contain calprotectin, a cytosolic protein complex involved in host
defense against Candida albicans. PLoS Pathog 2009, 5:e1000639.
35. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ,
Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL,
Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO,
Steinman L, Utz PJ: Autoantigen microarrays for multiplex
characterization of autoantibody responses. Nat Med 2002, 8:295-301.
36. Bua DJ, Kuo AJ, Cheung P, Liu CL, Migliori V, Espejo A, Casadio F, Bassi C,
Amati B, Bedford MT, Guccione E, Gozani O: Epigenome microarray
platform for proteome-wide dissection of chromatin-signaling networks.
PLoS One 2009, 4:e6789.
37. Noya O, Alarcon de Noya B: The multiple antigen blot assay (MABA): a
simple immunoenzymatic technique for simultaneous screening of
multiple antigens. Immunol Lett 1998, 63:53-56.
38. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ,
Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW:
Interferon-inducible gene expression signature in peripheral blood cells
of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
39. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-
Mortari A, Gregersen PK, Behrens TW, Baechler EC: Interferon-regulated
chemokines as biomarkers of systemic lupus erythematosus disease
activity: a validation study. Arthritis Rheum 2009, 60:3098-3107.
40. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, Williams G, Bauer J,
Gregersen P, Behrens T, Baechler E: Longitudinal expression of type I
interferon responsive genes in systemic lupus erythematosus. Lupus
2009, 18:980-989.
41. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R:
Identification of CRAMP, a cathelin-related antimicrobial peptide
expressed in the embryonic and adult mouse. J Biol Chem 1997,
272:13088-13093.
42. Gaines P, Berliner N: Differentiation and characterization of myeloid cells.
Curr Protoc Immunol 2005, Chapter 22, Unit 22F 25.
43. Tsai S, Collins SJ: A dominant negative retinoic acid receptor blocks
neutrophil differentiation at the promyelocyte stage. Proc Nat Acad Sci
USA 1993, 90:7153-7157.
44. Brinkmann V, Laube B, Abu Abed U, Goosmann C, Zychlinsky A: Neutrophil
extracellular traps: how to generate and visualize them. J Vis Exp 2010, ,
36: piii 1724.
45. von Kockritz-Blickwede M, Chow OA, Nizet V: Fetal calf serum contains
heat-stable nucleases that degrade neutrophil extracellular traps. Blood
2009, 114:5245-5246.
46. Baslund B, Wieslander J: A rapid and semi-quantitative method for the
detection of autoantibodies by multiple spot immunoassay. J Immunol
Methods 1994, 169:183-193.
47. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001,
98:5116-5121.
48. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display
of genome-wide expression patterns. Proc Natl Acad Sci USA 1998,
95:14863-14868.
49. Saldanha AJ: Java Treeview–extensible visualization of microarray data.
Bioinformatics 2004, 20:3246-3248.
50. Silverman GJ: Regulatory natural autoantibodies to apoptotic cells:
pallbearers and protectors. Arthritis Rheum 2011, 63:597-602.
51. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N: Resetting
the epigenetic histone code in the MRL-lpr/lpr mouse model of
lupus by histone deacetylase inhibition. J Proteome Res 2005,
4:2032-2042.
52. Burlingame R, Boey M, Starkebaum G, Rubin R: The central role of
chromatin in autoimmune responses to histones and DNA in systemic
lupus erythematosus. J Clin Invest 1994, 94:184.
53. Jenuwein T, Allis CD: Translating the histone code. Science 2001,
293:1074-1080.
54. Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C,
Landrigan A, Higgins JP, Tibshirani R, Utz PJ: IRF9 and STAT1 are required
for IgG autoantibody production and B cell expression of TLR7 in mice. J
Clin Invest 2008, 118:1417-1426.
55. Neeli I, Khan SN, Radic M: Histone deimination as a response to
inflammatory stimuli in neutrophils. J Immunol 2008, 180:1895-1902.
56. Grunstein M: Histone acetylation in chromatin structure and
transcription. Nature 1997, 389:349-352.
57. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM,
Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J,
Chaperot L, Kretzler M, Bruce AT, Kaplan MJ: Netting neutrophils induce
endothelial damage, infiltrate tissues, and expose immunostimulatory
molecules in systemic lupus erythematosus. J Immunol 2011, 187:538-552.
58. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS: Histone deacetylase
inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest
2003, 111:539-552.
59. Hu N, Qiu X, Luo Y, Yuan J, Li Y, Lei W, Zhang G, Zhou Y, Su Y, Lu Q:
Abnormal histone modification patterns in lupus CD4+ T cells. J
Rheumatol 2008, 35:804-810.
60. Forster N, Gallinat S, Jablonska J, Weiss S, Elsasser HP, Lutz W: p300 protein
acetyltransferase activity suppresses systemic lupus erythematosus-like
autoimmune disease in mice. J Immunol 2007, 178:6941-6948.
Liu et al. Arthritis Research & Therapy 2012, 14:R25
http://arthritis-research.com/content/14/1/R25
Page 13 of 14
61. Shoshan Y, Mevorach D: Accelerated autoimmune disease in MRL/MpJ-
Fas(lpr) but not in MRL/MpJ following immunization with high load of
syngeneic late apoptotic cells. Autoimmunity 2004, 37:103-109.
62. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z,
Grone HJ, Brinkmann V, Jenne DE: Netting neutrophils in autoimmune
small-vessel vasculitis. Nat Med 2009, 15:623-625.
63. Katz U, Zandman-Goddard G: Drug-induced lupus: an update. Autoimmun
Rev 2010, 10:46-50.
64. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB,
Esmon NL, Lupu F, Esmon CT: Extracellular histones are major mediators
of death in sepsis. Nat Med 2009, 15:1318-1321.
doi:10.1186/ar3707
Cite this article as: Liu et al.: Specific post-translational histone
modifications of neutrophil extracellular traps as immunogens and
potential targets of lupus autoantibodies. Arthritis Research & Therapy
2012 14:R25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. Arthritis Research & Therapy 2012, 14:R25
http://arthritis-research.com/content/14/1/R25
Page 14 of 14
